本季度信息
截至2026年6月30日止六个月，普华和顺实现营收3.94亿元，同比下降4.9%。同期经调整净利润为68.65百万元，同比下降42.4%。报告期内毛利为189.90百万元，同比下降10.8%，毛利率为48.2%。经营活动产生的现金净流入为89.93百万元，同比下降13.6%。此外，销售及市场推广开支为42.58百万元，同比下降2.7%，一般及行政开支为93.45百万元，同比上涨12.0%，研发投入为25.70百万元，同比上升14.3%。
业务分项
输液器业务实现营收80.42百万元，同比下降29.1%。血液净化业务营收3.08亿元，同比增长3.7%。再生医用生物材料业务收入5.18百万元，同比增长46.3%。各板块营收变化主要受带量采购范围及市场需求变动等因素的影响。
高管解读 （报告中无高管原话引用）
展望显示，普华和顺将继续加强研发投入与创新，优化产品矩阵与经营管理效率，并持续提升经营韧性，以在行业结构调整中捕捉新的发展机遇。公司还将深化本土市场，推进海外业务布局，为股东创造长期价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.